Literature DB >> 12349850

Insulin resistance and risk for stroke.

W N Kernan1, S E Inzucchi, C M Viscoli, L M Brass, D M Bravata, R I Horwitz.   

Abstract

BACKGROUND AND
PURPOSE: Resistance to insulin-mediated glucose uptake by peripheral tissues is a cardinal defect in type 2 diabetes mellitus. Insulin resistance is also common among nondiabetic individuals, and may be an important risk factor for stroke in both populations. The authors review the definition, epidemiology, and treatment of insulin resistance.
METHODS: The authors searched Medline (1977-2001) and reviewed bibliographies to identify pertinent English-language publications.
RESULTS: Insulin resistance is present in most patients with type 2 diabetes. It is also common among elderly persons, certain ethnic groups, and persons with hypertension, obesity, physical deconditioning, and vascular disease. The principal pathophysiologic defect is impaired intracellular signaling in muscle tissue leading to defective glycogen synthesis. Insulin resistance is associated with numerous metabolic, hematologic, and cellular events that promote atherosclerosis and coagulation. The association between insulin resistance and risk for stroke has been examined in four case-control studies and five prospective observational cohort studies. Six of the nine studies are methodologically sound and provide evidence that insulin resistance is associated with risk for stroke.
CONCLUSION: Insulin resistance may be a prevalent risk factor for stroke. New drugs can safely reduce insulin resistance and may have a role in stroke prevention.

Entities:  

Mesh:

Year:  2002        PMID: 12349850     DOI: 10.1212/wnl.59.6.809

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  60 in total

Review 1.  Systemic and brain metabolic dysfunction as a new paradigm for approaching Alzheimer's dementia.

Authors:  Vincenzo Giordano; Gianfranco Peluso; Maurizio Iannuccelli; Paola Benatti; Raffaella Nicolai; Menotti Calvani
Journal:  Neurochem Res       Date:  2006-08-17       Impact factor: 3.996

2.  Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial.

Authors:  J David Spence; Catherine M Viscoli; Silvio E Inzucchi; Jennifer Dearborn-Tomazos; Gary A Ford; Mark Gorman; Karen L Furie; Anne M Lovejoy; Lawrence H Young; Walter N Kernan
Journal:  JAMA Neurol       Date:  2019-05-01       Impact factor: 18.302

3.  The Relationship Between Migraine or Severe Headache and Chronic Health Conditions: A Cross-Sectional Study from the National Health Interview Survey 2013-2015.

Authors:  Mia T Minen; Judith Weissman; Gretchen E Tietjen
Journal:  Pain Med       Date:  2019-11-01       Impact factor: 3.750

Review 4.  Pioglitazone and cardiovascular risk reduction: time for a second look?

Authors:  Ana L Perdigoto; Lawrence H Young; Silvio E Inzucchi
Journal:  Cardiovasc Endocrinol       Date:  2017-05-17

5.  Clinical predictors and management of hemorrhagic transformation.

Authors:  Raphaella E Weiser; Kevin N Sheth
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

6.  Psychoneuroimmune implications of type 2 diabetes: redux.

Authors:  Jason C O'Connor; Daniel R Johnson; Gregory G Freund
Journal:  Immunol Allergy Clin North Am       Date:  2009-05       Impact factor: 3.479

7.  Edaravone offers neuroprotection for acute diabetic stroke patients.

Authors:  J Zheng; X Chen
Journal:  Ir J Med Sci       Date:  2015-11-23       Impact factor: 1.568

Review 8.  [Atherosclerosis and uremia: signifance of non-traditional risk factors].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2003-04-30       Impact factor: 1.704

9.  Clinical evaluation of insulin resistance and beta-cell function by the homeostasis model assessment in patients with systemic lupus erythematosus.

Authors:  Tim K Tso; Hui-Yu Huang; Chen-Kang Chang; Ying-Ju Liao; Wen-Nan Huang
Journal:  Clin Rheumatol       Date:  2004-05-18       Impact factor: 2.980

Review 10.  Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives.

Authors:  Dirk Sander; Mark T Kearney
Journal:  J Neurol       Date:  2009-04-29       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.